Special Report: Got 90 seconds? Then listen to Leo Lee, the CEO of regenerative medicine company Regeneus, following the appointment of two new board members.

Regeneus (ASX:RGS) announced this week that Dr John Chiplin, PhD and Dr Alan Dunton, M.D. have joined its board to support the company’s global growth strategy.

Dr Chiplin is Managing Director of Newstar Ventures and has significant operational, investment and transactions experienced in the international life science and technology industries.

Previously, he’s served as CEO at three publicly-listed software, biotechnology and cancer immunotherapy companies.

Dr Dunton is a senior pharmaceutical and biotechnology industry leader with experience across large pharmaceutical research and development organisations as well as private biotech companies focused on prescriptive treatment and the development and commercialisation of over-the-counter drugs on a global and local scale.

Regeneus’ CEO Leo Lee spoke with Stockhead about the potential impact of the new appointments.

Have a good idea for our next 90 Seconds With… segment? Email us at [email protected].

 

This story was developed in collaboration with Regeneus, a Stockhead advertiser at the time of publishing.
This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice. If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.

Featured Companies

You might be interested in